2. Academic Validation
  3. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR)

Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR)

  • J Med Chem. 2009 Feb 26;52(4):904-7. doi: 10.1021/jm8014124.
Brenton Flatt 1,  Richard Martin,  Tie-Lin Wang,  Paige Mahaney,  Brett Murphy,  Xiao-Hui Gu,  Paul Foster,  Jiali Li,  Parinaz Pircher,  Mary Petrowski,  Ira Schulman,  Stefan Westin,  Jay Wrobel,  Grace Yan,  Eric Bischoff,  Chris Daige,  Raju Mohan
Affiliations

Affiliation

  • 1 Department of Medicinal Chemistry, Exelixis Inc., 4757 Nexus Centre Drive, San Diego, California 92121, USA. bflatt@exelixis.com
PMID: 19159286 DOI: 10.1021/jm8014124
Abstract

Azepino[4,5-b]indoles have been identified as potent agonists of the farnesoid X receptor (FXR). In vitro and in vivo optimization has led to the discovery of 6m (XL335, WAY-362450) as a potent, selective, and orally bioavailable FXR Agonist (EC(50) = 4 nM, Eff = 149%). Oral administration of 6m to LDLR(-/-) mice results in lowering of Cholesterol and triglycerides. Chronic administration in an atherosclerosis model results in significant reduction in aortic arch lesions.

Figures
Products